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Fibrodysplasia ossificans progressiva (FOP) is a rare and intractable disorder characterized by extraskeletal bone formation through
endochondral ossification. FOP patients harbor gain-of-function mutations in ACVR1 (FOP-ACVR1), a type I receptor for bone
morphogenetic proteins. Despite numerous studies, no drugs have been approved for FOP. Here, we developed a high-throughput
screening (HTS) system focused on the constitutive activation of FOP-ACVR1 by utilizing a chondrogenic ATDC5 cell line that stably
expresses FOP-ACVR1. After HTS of 5,000 small-molecule compounds, we identified two hit compounds that are effective at sup-
pressing the enhanced chondrogenesis of FOP patient-derived induced pluripotent stem cells (FOP-iPSCs) and suppressed the hetero-
topic ossification (HO) of multiple model mice, including FOP-ACVR1 transgenic mice and HO model mice utilizing FOP-iPSCs.
Furthermore, we revealed that one of the hit compounds is an mTOR signaling modulator that indirectly inhibits mTOR signaling.
Our results demonstrate that these hit compounds could contribute to future drug repositioning and the mechanistic analysis of
mTOR signaling.
INTRODUCTION
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic
disease characterized by extraskeletal bone formation
in soft tissue, including skeletal muscle, ligament, and
tendon, where bone is not normally observed. Such
ectopic bones are formed through endochondral ossifica-
tion, a process whereby bone tissue replaces mature carti-
lage (Kaplan et al., 2005, 2007, 2008, 2012a; Shore et al.,
2005; Shore and Kaplan, 2010; Zuscik et al., 2008). Approx-
imately 90% of FOP patients share an R206H (617G>A)
point mutation in the intracellular glycine- and serine-
rich domain of ACVR1 (Shore et al., 2006), a type I receptor
for bone morphogenetic proteins (BMPs) (Canalis et al.,
2003; Gu et al., 1999; Hogan, 1996; Massague et al.,
2000; Mishina et al., 1999; Miyazono et al., 2010; Mueller
and Nickel, 2012; Piek et al., 1999; Urist, 1965; Wozney
et al., 1988). This mutated ACVR1 (FOP-ACVR1) has
been shown to confer ligand-independent constitutive
activity and ligand-dependent hyperactivity in BMP
signaling (Billings et al., 2008; Chaikuad et al., 2012;
Fukuda et al., 2008). Moreover, by utilizing FOP patient-
derived induced pluripotent stem cells (FOP-iPSCs) and
FOP-ACVR1 conditional-on knockin mice, it has been
shown that as its neofunction FOP-ACVR1 abnormally
transduces BMP signaling in response to activin A, a mole-
cule that normally transduces transforming growth factor
b (TGF-b) signaling but not BMP signaling (Hatsell et al.,
2015; Hino et al., 2015).
A number of studies have revealed drug candidates for
FOP, including direct kinase inhibitors of the catalytic
domain of BMP type I receptors, which consequently sup-
press the phosphorylation of the downstream effectors
SMAD1/5/8 (Engers et al., 2013; Hamasaki et al., 2012;
Hao et al., 2010; Mohedas et al., 2013; Sanvitale et al.,
2013; Yu et al., 2008); RARg agonists, which reduce the
expression of SMAD1/5/8 by protein degradation (Chakka-
lakal et al., 2016; Pavey et al., 2016; Shimono et al., 2011;
Sinha et al., 2016); an inhibitor of activin A signaling by
an activin A-specific neutralizing antibody (Hatsell et al.,
2015; Hino et al., 2015); mechanistic target of rapamycin
(mTOR) inhibitors, which target enhanced chondrogene-
sis, hypoxic signaling, and inflammatory signaling (Agar-
wal et al., 2016; Hino et al., 2017); and others (Brennan
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et al., 2017; Cappato et al., 2016; Convente et al., 2017; Ka-
plan et al., 2012b; Kitoh et al., 2013; Takahashi et al., 2012;
Wang et al., 2016). Among these drug candidates, the RARg
agonist palovarotene, the anti-activin A antibody, and the
mTOR inhibitor rapamycin are now under clinical trial.
Although many attempts are ongoing, no drug is available
for FOP, and a limited number of target molecules is
reported.
For the identification of potential drug target molecules
or pathways, phenotypic screenings that focus on the FOP
pathology are an attractive approach but generally highly
challenging to develop (Moffat et al., 2017). We previously
reported phenotypic screening to modulate the enhanced
chondrogenesis of FOP-iPSC-derived induced mesen-
chymal stromal cells (FOP-iMSCs) triggered by activin A
(Hino et al., 2017). In that strategy, our concept was
mainly based on the knowledge that trauma, surgery,
inflammation, or viral infection often evoke episodic
flare-ups that precede heterotopic ossification (HO) in
FOP (Kaplan et al., 2005) and that one of the crucial initi-
ators of HO is activin A activation (Hatsell et al., 2015;
Hino et al., 2015). In contrast, another study reported a
distinct feature of FOP pathology in that about half of
FOP patients experienced the progression of HO without
apparent flares, injury, or related events (Pignolo et al.,
2016). Accordingly, we assumed that this pathology might
be caused by ligand-independent constitutive activity
such that FOP-ACVR1 transduces BMP signaling without
ligand binding.
Featuring ligand-independent constitutive activity, here
we established a phenotypic assay-based high-throughput
screening (HTS) system focused on alkaline phosphatase
(ALP), a well-established prehypertrophic chondrogenic
marker (Zuscik et al., 2008), utilizing a chondrogenic
ATDC5 cell line (Akiyama et al., 2000; Shukunami et al.,
1997) that stably expresses FOP-ACVR1 (ATDC5/FOP-
ACVR1). After HTS of approximately 5,000 small-mole-
cule compounds, we identified three hit compounds:
AZD0530 (also known as saracatinib), PD 161570, and
TAK 165 (also known as mubritinib). These compounds
suppressed the enhanced chondrogenesis in FOP-iMSCs,
a critical step of HO in the FOP pathology. We subse-
quently showed their therapeutic effects on HO in three
different in vivo models: a BMP-7-induced HO model,
FOP model mice expressing FOP-ACVR1, and a FOP-
iPSC-based HO model in which ectopic bones derived
from FOP patient-derived cells are formed in mice. Mech-
anism-of-action studies indicated that AZD0530 and PD
161570 were inhibitors of both BMP and TGF-b signaling.
On the other hand, TAK 165 was an mTOR signaling
modulator that indirectly controlled mTOR signaling.
These data extend the molecular basis of the HO induced
in FOP patients.
RESULTS
Development of an HTS System Focused on
Constitutive Activity of FOP-ACVR1
FOP-ACVR1 has been shown to render ligand-independent
constitutive activity and ligand-dependent hyperactivity in
BMP signaling (Billings et al., 2008; Chaikuad et al., 2012;
Fukuda et al., 2008), and direct ACVR1 kinase inhibitors of
the catalytic domain of BMP type I receptors are reported
(Engers et al., 2013; Hamasaki et al., 2012; Hao et al., 2010;
Mohedas et al., 2013; Sanvitale et al., 2013; Yu et al.,
2008).Althoughthese inhibitors arepromisingandeffective
on FOP model mice (Dey et al., 2016; Yu et al., 2008), new
drug candidates thatmodulate FOPpathological conditions
throughundescribedmechanisms are also beneficial. There-
fore, to screen direct BMP signaling inhibitors and FOP
phenotype modulators at the same time, we focused on a
chondrogenic cell line, ATDC5. ATDC5 cells are known to
increase the expressionofALPbyBMPstimulation in several
days (Akiyamaet al., 2000; Shukunami et al., 1997), andALP
activity can be detected by a chromogenic phosphatase sub-
strate in anHTS format. Although ALP is also known to be a
pluripotent marker, it is upregulated during chondrogenic
induction consistently with other chondrogenic markers
in ATDC5 cells (Shukunami et al., 1997), indicating that
ALP is a chondrogenicmarker at least inATDC5 cells.Wede-
signed an ACVR1 expression vector utilizing the doxycy-
cline (Dox)-inducible vector KW111 (Hayakawa et al.,
2013;Woltjen et al., 2009) andgeneratedATDC5cells stably
expressing FOP-ACVR1 (R206H) or wild-type (WT)-ACVR1
(Figure 1A). After Dox treatment, ACVR1 expression was
increased in a concentration-dependent manner (Figures
1B andS1). Expectedly,withoutBMPstimulation,ALPactiv-
ity was increased in ATDC5 cells expressing FOP-ACVR1,
but not in WT-ACVR1 (Figure 1C). This result indicates the
constitutive activity of BMP signaling was triggered by
FOP-ACVR1 expression. In addition to this constitutive
activity, hyperactivity against BMP-4 and acquired respon-
siveness to activin A were observed in ATDC5-expressing
FOP-ACVR1 (Figure 1D). These results indicated the validity
of our assay system. DMH-1, a direct ACVR1 kinase inhibi-
tor, suppressed the ALP activity of ATDC5 cells expressing
FOP-ACVR1 without BMP stimulation in a concentration-
dependent manner, also demonstrating that the constitu-
tive activity of BMP signaling can bemeasured by ALP activ-
ity (Figure 1E). These results indicate that Dox-inducible
ATDC5cells enableus to screen inhibitorsagainst theconsti-
tutive activity of FOP-ACVR1.
HTS and Follow-Up Screens Identified Seven Hit
Compounds
Utilizing this HTS system, we performed a first screening
(n = 2; test compounds = 1 mM, Figure 2A) against our
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HTS library, which contains approximately 5,000 small-
molecule compounds, most of which are marketed or
bioactive (see also Supplemental Experimental Proced-
ures). The scatterplot distribution of ALP activity and cell
viability (Figures 2B and 2C), and Z0 factor and S/B ratio
(Figures 2D and 2E) confirmed the validity of the HTS
campaign. From the first screening, we obtained 160 hit
compounds that fulfilled the criteria that more than 40%
inhibition of ALP activity against DMSO control cells, less
than 40% inhibition of viability and more than 20% of
margin (inhibition of ALP activity [%] minus inhibition
of viability [%]). A second screening was performed against
the above 160 compounds (n = 2; test compounds = 0.1,
0.3, 1, 3 mM), and we identified 79 hit compounds that
showed 40% inhibition of ALP activity against DMSO con-
trol cells andmore than 50% ofmargin at any dose (Figures
2F and S2). A summary of HTS is shown in Figure 2G.
Among them, RARg agonists suppressed ALP activity, indi-
cating the accuracy of our HTS system. To explore com-
pounds that have potential to identify new mechanisms
or contribute to future drug repositioning, we selected
14 compounds and performed a detailed concentration-
dependent assay (Figure 3A). As a result, we identified seven
compounds that showed stronger IC50 (<500 nM) and
less toxicity (viability at 10 mM >50%) through our HTS
campaign focused on the constitutive activity of FOP-
ACVR1 (Figure 3B, red).
Further Validation of Seven Hit Compounds in FOP
Patient-Derived iPSCs
To predict these seven compounds’ therapeutic effects on
FOP patients, we performed a FOP-iPSC-based chondro-
genic assay. In this assay system, FOP-iMSCs (Fukuta
et al., 2014; Hino et al., 2015, 2017; Matsumoto et al.,
2015), a putative cell of origin of ectopic chondrogenesis,
were treated with activin A, and the inhibitory effect of
seven hit compounds was assessed at 1 mM (Figure 4A).
Among them, AZD0530, PD 161570, and TAK 165 showed
potent inhibition on glycosaminoglycan (GAG) produc-
tion, which represents the amount of extracellular matrix
secreted by chondrocytes. A detailed analysis against these
three compounds revealed a concentration-dependent
inhibitory effect on GAG in the chondrogenic assay of
FOP-iMSCs (Figure 4B). Alcian blue staining, which stains
acidic polysaccharides such as GAG in chondrocytes, also
confirmed drug activity (Figure 4C). These results indicate
that AZD0530, PD 161570, and TAK 165 have the potential
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Figure 1. Construction and Validation of
the Compound Screening System
(A) Vector map of the Dox-inducible ACVR1
expression vector.
(B) The expression of ACVR1 and mCherry in
ATDC5/FOP-ACVR1 24 hr after 2 ng/mL Dox
treatment. Scale bar, 100 mm.
(C) ALP activity of ATDC5/WT-ACVR1 or FOP-
ACVR1 72 hr after Dox treatment.
(D) Concentration response curves of BMP-4
and activin A in ATDC5/WT-ACVR1 or FOP-
ACVR1 72 hr after 3 ng/mL Dox and ligand
treatment.
(E) DMH-1 (ACVR1 kinase inhibitor) inhibited
the ALP activity but not the viability
(AlamarBlue) of ATDC5/FOP-ACVR1. ALP and
AlamarBlue assays were performed 72 hr after
Dox and DMH-1 treatment.
Results are the mean ± SE, n = 1 (C) or bio-
logical triplicate in three independent ex-
periments (D and E).
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In Vivo Therapeutic Effects of AZD0530 and TAK 165
Next, the therapeutic effects of these drug candidates on
FOP model mice were evaluated. We focused on AZD0530
and TAK 165 because they are applicable to in vivo experi-
ments (Hennequin et al., 2006; Nagasawa et al., 2006). Pre-
viously, we generated FOP model mice that conditionally
express hFOP-ACVR1 (R206H) by Dox administration
and develop HO by muscle injury using cardiotoxin
(CTX) (Hino et al., 2017). The intraperitoneal administra-
tion of AZD0530 or TAK 165 significantly suppressed the
HO in these mice (Figures 5A–5C). In the CTX-injected
site, we observed positive staining for safranin O (acidic
proteoglycan, an extracellular matrix protein of chondro-
cytes), von Kossa (calcium deposition), and COL1 (bone
marker) (Figure 5D, vehicle). On the other hand, mice
administered AZD0530 or TAK 165 seemed to show less
positive staining for von Kossa or COL1 (Figure 5D,
AZD0530 and TAK 165). No apparent differences in body
weight change was observed in mice administered
AZD0530 or TAK 165 compared with vehicle (Figure 5E).
These observations demonstrated that AZD0530 and TAK
165 are effective at suppressing HO in FOP model mice.
These compounds’ therapeutic effects were also confirmed
in a BMP-7-induced HO model using WT mice (Figure S3).
Furthermore, we validated whether AZD0530 and TAK 165
have the potential to suppress the HO of FOP patient-
derived cells in vivo. We previously reported a human
FOP-iPSC-based in vivo model (Hino et al., 2015, 2017). In
this humanized FOP model, the transplantation of FOP-
iMSCs and activin A-expressing cells into mice induces
FOP patient-derived heterotopic bone in vivo. Notably,
the administration of AZD0530 or TAK 165 significantly
suppressed HO in these mice (Figures 6A–6C). Hypertro-
phic chondrocytes (based on safranin O and von Kossa
staining) and von Kossa- and COL1-positive bone regions
seemed to be fewer in mice administered AZD0530 or
TAK 165 (Figure 6D). Because a large number of anti-
human-specific vimentin-positive cells were observed in
the AZD0530 and TAK 165-treated groups (Figure 6D), we
could conclude that the therapeutic effect of these com-
pounds was not due to the death of the human trans-
planted cells but rather the suppression of HO. In these ex-
periments, neither AZD0530 nor TAK 165 administration
decreased body weight (Figures 5E, 6E, and S3D), and the
dosing used was comparable with that in previous studies
(Hennequin et al., 2006; Nagasawa et al., 2006). TAK 165
in particular did not impair the chondrogenesis of normal
chondrocytes (Figures S4A–S4C), normal skeletal develop-
ment in vivo (Figures S4D and S4E), or wound healing
in vitro (Figures S4F and S4G). Thus, we concluded the
HO suppression was not primarily caused by toxicity,
although further in vivo assessment might be preferable.
Taken together, AZD0530 and TAK 165 are promising
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Figure 2. Schematic and Detailed Results of High-Throughput Screening
(A) Schematic of the first screening.
(B–E) Scatterplot distribution of ALP activity (B), viability (C), Z0 factor (D), and S/B ratio (E) from the first screening against 4,892
compounds.
(F) Classification of 79 hit compounds through the second screening.
(G) Results of the HTS campaign and follow-up screens.
Biological duplicates (B–F).
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AB
Name IC50, nM Viability (%) @10 µM Highest stage Putative mechanism
Calcipotriol 0.3 80 Launched Vitamin D derivative
Calcitriol 0.4 81 Launched Vitamin D derivative
AZD0530 4 56 Phase II Src, Bcr-Abl inhibitor
BIRB 796 9 99 Phase III p38 MAPK inhibitor 
LY2228820 11 75 Phase II p38 MAPK inhibitor 
TAK 165 39 117 Phase I ERBB2 inhibitor
AZD8055 77 25 Phase I mTORC1/2 inhibitor
BEZ235 87 21 Phase II PI3K, mTORC1/2 inhibitor
SN 38 98 17 Phase II Topoisomerase-I inhibitor
PIKfyve Inhibitor 283 12 Preclinical PIKfyve Inhibitor
PD 161570 317 63 Preclinical FGFR inhibitor
Alfacalcidol 526 54 Launched Vitamin D derivative
NVP-ADW742 6569 -1 Preclinical IGF-1R inhibitor 
1-Naphthyl PP1 12220 83 Preclinical Src family kinase inhibitor










(legend on next page)
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patient-derived cells in vivo in addition to the HO of FOP
model mice.
Mechanisms of Action of AZD0530, PD 161570, and
TAK 165
Finally, we analyzed the mechanisms of action of
AZD0530, PD 161570, and TAK 165 on the chondrogenesis
of FOP-iMSCs. Because it is known that BMP and TGF-b
signaling are crucial in the chondrogenesis of FOP (Hino
et al., 2015, 2017) and because our HTS system can detect
BMP inhibitors, we assessed the direct effects of the three
drugs on BMP and TGF-b signaling. AZD0530 and PD
161570 inhibited both BRE-Luc (BMP-specific luciferase re-
porter construct) and CAGA-Luc (TGF-b-responsive lucif-
erase reporter construct) (Figures 7A and 7B). Therefore,
we concluded AZD0530 and PD 161570 were BMP and
TGF-b signaling dual inhibitors, and their mechanisms of
action could contribute to the suppression of the chondro-
genesis of FOP-iMSCs because they inhibited both path-
ways at similar drug concentration ranges during the chon-
drogenesis of FOP-iMSCs (Figure 4B). This result is in
accordance with a previous study showing that AZD0530
inhibited BMP type I receptors (Lewis and Prywes, 2013).
On the contrary, TAK 165 did not affect these signaling
pathways. TAK 165 is an ERBB2 (also known as HER2)-
selective kinase inhibitor (Anastassiadis et al., 2011; Naga-
sawa et al., 2006). To check the importance of ERBB2 inhi-
bition in chondrogenesis, we performed a loss-of-function
study using small interfering RNA (siRNA). Knockdown of
ERBB2 did not decrease GAG in the chondrogenesis of
FOP-iMSCs (Figure 7C). Furthermore, another ERBB2-se-
lective inhibitor (CP-724714), an ERBB1/2-selective inhib-
itor (lapatinib), or ERBB2-selective neutralizing antibodies
(trastuzumab and pertuzumab) showed no effect on
GAG in the chondrogenesis of FOP-iMSCs (Figures S5A
and S5B). Given these results, the mechanism of action
of TAK 165 was not through ERBB2 inhibition. We further
investigated the effect of TAK 165 on TGF-b3-induced
chondrogenesis in FOP-iMSCs and activin A-induced
chondrogenesis in resFOP-iMSCs, in which the mutant
ACVR1 was corrected to WT (Matsumoto et al., 2015) (Fig-
ures S5C and S5D). These results indicate that TAK 165
showed stronger effects on FOP cells than on normal cells.
Recently, ourselves and Agarwal et al. have separately un-
covered the impact of inhibiting mTOR signaling on the
HO of FOP model mice and FOP-iMSCs (Agarwal et al.,
2016; Hino et al., 2017). Therefore, we checked TAK
165’s effect on mTOR signaling. First, to test whether
TAK 165 is a direct inhibitor, we monitored the phosphor-
ylation of S6 (p-S6), a well-known mTOR signaling surro-
gate marker, for 2 hr after treatment with TAK 165 in
FOP-iMSCs cultured in 10% fetal bovine serum (FBS) (Fig-
ure 7D). In this condition, a strong p-S6 signal was de-
tected. The mTOR inhibitor rapamycin decreased p-S6
levels, but TAK 165 did not. Next, we checked for indirect
effects of TAK 165 on mTOR signaling in the chondrogen-
esis assay of FOP-iMSCs stimulated by activin A. After
24-hr stimulation with TAK 165 or CP-724714, no effects
were observed on p-S6 (Figure 7E). Interestingly however,
after 7 days of stimulation with TAK 165 but not
CP-724714, p-S6 was dramatically decreased (Figure 7F).
As expected, AZD0530 and PD 161570 significantly in-
hibited p-S6 levels from 2 hr after treatment (Figure S6),
indicating that TAK 165 acts through a distinct mecha-
nism. In addition, we performed an unbiased transcrip-
tome analysis of FOP-iMSCs 7 days after inducing chon-
drogenesis by activin A (Figure S7). TAK 165, but not
other ERBB2 inhibitors, affected genes that are involved
in chondrogenesis or osteogenesis (‘‘Role of Osteoblasts,
Osteoclasts, and Chondrocytes in Rheumatoid Arthritis’’
in Figure S7B). These results indicate that TAK 165 indi-
rectly modulated mTOR signaling and suppressed the
chondrogenesis and HO of FOP.
DISCUSSION
In this report, we identified TAK 165 as a drug candidate for
FOP. It is reported that TAK 165 is a selective inhibitor of
ERBB2, a receptor tyrosine kinase often amplified or
mutated in several cancers (Moasser, 2007). It is common
that kinase inhibitors targeting catalytic domains show
less selectivity, but interestingly TAK 165 is highly selective
for ERBB2 against a panel of 300 recombinant protein ki-
nases, presumably due to the fact that TAK 165 is an allo-
steric inhibitor of ERBB2 (Anastassiadis et al., 2011).
Regardless of TAK 165’s high selectivity to ERBB2, the sup-
pression of chondrogenesis and HO by TAK 165 was not
caused by ERBB2 inhibition but by indirect mTOR
signaling inhibition (Figure 7). TAK 165 inhibited the
ALP activity of constitutively activated FOP-ACVR1 in
ATDC5 (Figure 3) and the enhanced chondrogenesis of
FOP-iMSCs triggered by activin A (Figure 4). TAK 165 also
modulated chondrogenesis-related pathways (Figure S7).
Figure 3. Detailed Dose-Response Assay Results of 14 Hit Compounds
(A) Dose-response curves of 14 hit compounds. ALP assay and AlamarBlue assay were performed using the same protocol as the HTS.
(B) IC50 values and viability (%) at 10 mM in the dose-response assay, highest stage, and putative mechanism of 14 hit compounds are
shown. Seven compounds (red) satisfied the criteria (IC50 of ALP assay <500 nM and viability at 10 mM >50%).
Results are the mean ± SE, biological triplicates.
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These results suggested that TAK 165 affected chondrogen-
esis through indirect mTOR signalingmodulation. Because
TAK 165 showed obviously different effects on Alcian blue
staining (Figure 4C), BMP and TGF-b signaling (Figures 7A
and 7B), and mTOR signaling compared with other HTS
hits (Figures 6D–6F and S6), TAK 165 might be useful for
future concurrent treatment with other direct inhibitors.
A detailed mechanism of action and the identification of
direct targets of TAK 165 remain important issues awaiting
future clarification.
To identify potential mechanisms that suppress the
enhanced chondrogenesis of FOP, we developed an HTS
system that focuses on the constitutive activity of FOP-
ACVR1. Although we previously focused on activin A-trig-
gered enhanced chondrogenesis, inspired by the recent
report showing that a substantial number of FOP patients
experience the progression of HO without apparent flares
(Pignolo et al., 2016), we adopted the constitutive activity
of FOP-ACVR1 for phenotypic screening system. We
screened a library of about 5,000 small-molecule com-
pounds and finally identified hit compounds that were
effective in multiple HO model mice (Figures 5, 6, and
S3). However, although effective, the effect of the hit com-
pounds had high variability. Improving in vivomodels will
reduce variation caused by the incomplete purity of the
mouse strain (Figure 5) or by the technical challenges of
the transplantation assay (Figure 6). Another important
issue is how to enhance the efficacy of our compounds
in vivo. Since the hit compounds are prototypes or lead




Figure 4. AZD0530, PD 161570, and TAK
165 Suppressed the Chondrogenic Induc-
tion of FOP-iMSCs
(A) The inhibitory effect of seven hit com-
pounds on the chondrogenic induction of
FOP-iMSCs. The cells were harvested 7 days
after chondrogenic induction, which was
performed with or without activin A and in-
hibitors (1 mM).
(B) AZD0530, PD 161570, and TAK 165 sup-
pressed the chondrogenic induction of FOP-
iMSCs in a dose-dependent manner.
(C) Alcian blue staining of DMH-1, AZD0530,
PD 161570, and TAK 165.
Results are the mean ± SE, biological tripli-
cates used FOP-iPSCs (vFOP4-1) (A and B).
n.s., no significant difference; ***p < 0.001
by Dunnett’s multiple comparisons t test
compared with the DMSO treatment control
with activin A. Scale bar, 200 mm.
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be not well studied, hampering assessment of the maximal
dose that suppresses HO.
There are two types of approaches in FOP drug discovery.
The first approach is target-based and focuses on FOP-
ACVR1 itself, e.g., kinase inhibition of FOP-ACVR1 or
downregulation of Acvr1 expression (Cappato et al., 2016;
Engers et al., 2013; Hamasaki et al., 2012; Hao et al.,
2010; Mohedas et al., 2013; Sanvitale et al., 2013; Yu
et al., 2008). The second approach is phenotypic screening
and focuses on HO-related phenotypes, for example,
enhanced chondrogenesis, osteogenesis, and so forth
(Shore and Kaplan, 2010). The former approach is quite
logical and promising because it suppresses causal genes
in FOP, but in general highly selective kinase inhibition is
extremely challenging (Anastassiadis et al., 2011). On the
other hand, phenotypic screening could highlight the
most effective and/or novel mechanism that underlies
FOP pathology, although the challenge here is to develop
a robust system that screens compounds or gives further
validation of candidates (Hino et al., 2017; Moffat et al.,
2017). In this study, we performed HTS of inhibitors for
ALP activity triggered by the constitutive activity of FOP-
ACVR1 in the chondrogenic cell line ATDC5. Since ALP is





Figure 5. AZD0530 and TAK 165 Sup-
pressed HO in FOP-ACVR1 Conditional
Transgenic Mice
(A) Schematic of the in vivo efficacy study
utilized FOP-ACVR1 conditional transgenic
mice. Intraperitoneal (i.p.) administration of
5 mg/kg AZD0530 and TAK 165 (once daily,
five times a week) suppressed the HO in FOP-
ACVR1 (R206H) conditional transgenic mice.
HO was induced by muscle injury triggered by
cardiotoxin (CTX) injection and oral admin-
istration of Dox. Three weeks after CTX in-
jection and drug administration, mice were
analyzed.
(B) X-rays (upper panels) and mCT (lower
panels) observations. Scale bars, 10 mm.
(C) Average heterotopic bone volume.
(D) Histological analysis of the CTX-injected
region. H&E staining, safranin O staining
(acidic proteoglycan), von Kossa staining
(calcium), and anti-COL1 (bone) staining are
shown. Scale bars, 100 mm (H&E, safranin O,
and von Kossa) and 500 mm (COL1 and
hVimentin).
(E) Body weight change (%) of mice admin-
istered compounds.
Results are the mean ± standard error (SE),
n = 6 (vehicle), n = 7 (AZD0530), or n = 5 (TAK
165). **p < 0.01 by Dunnett’s multiple com-
parisons t test compared with vehicle treat-
ment group (C). No significant differences
between the AZD- or TAK-administered group
compared with the vehicle group in two-
way repeated-measures ANOVA followed by
Dunnett’s multiple comparisons t test (E).
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our HTS platform is a successful example of phenotypic
screening for FOP. Consequently, we identified TAK 165,
an mTOR signaling modulator that indirectly inhibits
mTOR signaling, in addition to two direct ACVR1 kinase
inhibitors (AZD0530 and PD 161570). Thus, pheno-
typic screening could contribute to understanding FOP
pathophysiology.
In FOP patients, two phases, inflammation and the
destruction of connective tissues (phase 1) and bone forma-
tion (phase 2), were proposed in the progression of HO
(Shore and Kaplan, 2010), and each phenotype is a poten-
tial target for intervention. The suppression of phase 1 by
anti-inflammatory drugs such as oral corticosteroids shows
limited effects on FOP patients, but other approaches such
as mast cell inhibitors might become new drug candidates
(Brennan et al., 2017; Convente et al., 2017), although a
future clinical trial is needed to prove the efficacy and
side effects in FOP patients. Phase 2 can be further subdi-
vided into three stages: fibroproliferation and angiogenesis





Figure 6. AZD0530 and TAK 165 Sup-
pressed HO Derived from FOP-iMSCs In Vivo
(A) Schematic of the in vivo efficacy study
utilized a human FOP-iPSC-based in vivo
model. Intraperitoneal (i.p.) administration
of 5 mg/kg AZD0530 or TAK 165 (once daily,
five times a week) suppressed the HO derived
from FOP-iMSCs triggered by activin A. Eight
weeks after transplantation and drug admin-
istration, mice were analyzed.
(B) X-ray (upper panels) and mCT (lower
panels) observations. Scale bars, 10 mm.
(C) Average heterotopic bone volume.
(D) Histological analysis of the cell-trans-
planted region. H&E, safranin O, von Kossa,
anti-COL1, and anti-human vimentin staining
are shown. Scale bars, 100 mm (H&E, safranin
O, and von Kossa) and 500 mm (COL1 and
hVimentin).
(E) Body weight change (%) of mice admin-
istered compounds.
Results are the mean ± SE, n = 8 (vehicle),
n = 10 (AZD0530), or n = 12 (TAK165).
*p < 0.05 by Dunnett’s multiple comparisons
t test compared with vehicle treatment group
(C). No significant differences between the
AZD- or TAK-administered group compared
with the vehicle group in two-way repeated-
measures ANOVA followed by Dunnett’s mul-
tiple comparisons t test (E).
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focused on stage 2B, chondrogenesis, in both this and a
previous study (Hino et al., 2017), because we assumed
that the inhibition of chondrogenesis might not cause
serious side effects since little or no chondrogenesis occurs
in adults (Falah et al., 2010). On the other hand, as bone re-
modeling is a lifelong process (Maggioli and Stagi, 2017),
the inhibition of stage 2C (osteogenesis) might evoke
adverse effects, such as fracture or osteoporosis, regardless
of anyHO suppression. Although stage 2A (enhanced fibro-
proliferation) is often observed in the HO of FOP patients,
no defined molecules have been reported for this process.
Thus, a phenotypic screening focused on fibroproliferation
could shed light on novel mechanisms of FOP. Three
studies have identified the cell of origin of HO in FOP
modelmice (Agarwal et al., 2017; Dey et al., 2016; Lees-She-
pard et al., 2018), and iMSCs or paraxial mesoderm-derived
MSC-like cells can be induced from FOP-iPSCs (Hino et al.,
2015, 2017; Matsumoto et al., 2015; Nakajima et al., 2018);
therefore, these cells could be applicable to future pheno-
typic screenings for the inhibition of stage 2A. Combina-
tion therapy targeting multiple phases could be the best
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Figure 7. Mechanism of Action of
AZD0530, PD 161570, and TAK 165
(A and B) AZD0530 and PD 161570, but not
TAK 165, inhibited both BMP signaling (A)
and TGF-b signaling (B). FOP-iMSCs tran-
siently transfected with BRE-Luc (A) or CAGA-
Luc (B) with CMV-Renilla were stimulated
with activin A and compounds for 16 hr (A) or
3 hr (B).
(C) ERBB2 knockdown did not reduce GAG
content in the chondrogenic assay of FOP-
iMSCs. One day after siRNA transfection,
chondrogenic induction with activin A was
initiated, and after 7 days the cells were
harvested.
(D–F) TAK 165 indirectly inhibited mTOR
signaling. (D) TAK 165 did not inhibit mTOR
signaling directly, as assessed by western
blotting of the phosphorylation of S6 (p-S6),
a surrogate marker of mTORC1 activity. FOP-
iMSCs cultured with 10% FBS were treated
with 100 nM rapamycin (Rapa) or TAK 165
(TAK) for 2 hr, and the cells were harvested.
(E and F) TAK 165 indirectly inhibited
p-S6 during chondrogenic induction with
activin A. After 24 hr or 7 days of chondro-
genic induction of FOP-iMSCs with activin A
and test compounds, the cells were har-
vested. 1 mM TAK, 1 mM CP (CP-724714,
another selective ERBB2 inhibitor), or 10 nM
Rapa were applied in the experiments.
Results are the mean ± SE of biological qua-
druplicates (A and B) or triplicates (C–F)
using FOP-iPSCs (vFOP4-1). n.s., no signifi-
cant difference; **p < 0.01, ***p < 0.001
by Dunnett’s multiple comparisons t test
compared with the siRNA-transfected nega-
tive control and activin A (C) or with the
DMSO treatment control and activin A (A, B,
D–F).
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EXPERIMENTAL PROCEDURES
Full experimental procedures and associated references are avail-
able in Supplemental Experimental Procedures.
Study Approval
All experimental protocols dealing with human subjects were
approved by the Ethics Committee of the Department of Medicine
and Graduate School of Medicine, Kyoto University. Written
informed consent was provided by each donor. All animal experi-
ments were approved by the institutional animal committee of
Kyoto University.
Chemicals Libraries
All chemical libraries were purchased from the suppliers listed in
Supplemental Experimental Procedures. Almost all compounds
were bioactive and/or annotated.
Cell Culture
ATDC5 cells were maintained in DMEM/F-12 (Thermo Fisher Sci-
entific) supplemented with 5% (v/v) FBS (Nichirei). The FOP-iPSCs
used in this study (previously described as vFOP4-1 [Matsumoto
et al., 2013]) harbor the R206H heterozygous mutation in
ACVR1, and gene-corrected resFOP-iPSCs were generated by
BAC-based homologous recombination. These cells fulfilled
several criteria for iPSCs including the expression of pluripotent
markers, teratoma formation, normal karyotype, andmorphology.
Growth and gene expression profiles of the resFOP-iPSC clones
were indistinguishable from the original FOP-iPSCs (Matsumoto
et al., 2015); however, remarkably distinct responsiveness to acti-
vin A was observed (Hino et al., 2015).
ALP Assay
ATDC5/FOP-ACVR1 cells were plated in 96-well white plates
(2,000 cells/well/40 mL, Corning) in DMEM/F-12 supplemented
with 5% (v/v) FBS. Two hours after incubation at 37C under 5%
CO2, 10 mL of test compounds (final 1 mM) was added, and the
assay plates were incubated at 37C under 5% CO2. After 3 days
of incubation, ALP activity was measured using an Amplite Color-
imetric Alkaline Phosphatase Assay Kit (AAT Bioquest) according
to the manufacturer’s protocol.
2D Chondrogenic Induction
Chondrogenic induction was performed, and differentiation prop-
erties were assayed as previously described (Hino et al., 2015; Nasu
et al., 2013; Umeda et al., 2012).
In Vivo Experiments
hFOP-ACVR1 conditional transgenicmice (Beard et al., 2006; Hino
et al., 2017; Ohnishi et al., 2014; Yamada et al., 2013), BMP-7-
induced HOmodel mice (Hino et al., 2017), and activin A-induced
HO model mice transplanted with FOP-iMSCs (Hino et al., 2017)
were intraperitoneally administered 5 mg/kg AZD0530, TAK 165,
or rapamycin (once daily, five times a week) and analyzed as previ-
ously described (Hino et al., 2017).
Statistics
The statistical significance of all experiments was calculated by
Prism 6 (GraphPad Software). p values less than 0.05 were consid-
ered statistically significant.
ACCESSION NUMBERS
Microarray data were deposited in the GEO of NCBI under the
accession number GEO: GSE108771.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and seven figures and can be found with this article
online at https://doi.org/10.1016/j.stemcr.2018.10.007.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Study approval. All experimental protocols dealing with human subjects were approved by the Ethics 
Committee of the Department of Medicine and Graduate School of Medicine, Kyoto University. Written 
informed consent was provided by each donor. All animal experiments were approved by the institutional 
animal committee of Kyoto University. 
 
Cell culture. ATDC5 cells were maintained in DMEM/F-12 (Thermo Fisher Scientific) supplemented with 5% 
(v/v) FBS (Nichirei). iPSCs were maintained in primate ES cell medium (ReproCELL) supplemented with 4 
ng/mL recombinant human FGF2 (Wako Pure Chemical). To induce induced neural crest cells (iNCCs), 
mTeSR1 medium (STEMCELL Technology) was used for the feeder-free culture of iPSCs. The induction and 
maintenance of iNCCs and iMSCs derived from iPSCs were previously described (Fukuta et al., 2014; 
Matsumoto et al., 2015). Briefly, iNCCs were induced in chemically defined medium (CDM) supplemented 
with 10 µM SB-431542 and 1 µM CHIR99021 for 7 days. iNCCs were maintained in CDM supplemented with 
10 µM SB-431542, 20 ng/mL FGF2 and 20 ng/mL recombinant human EGF (R&D Systems) for up to 20 
passages. iMSCs were induced and maintained in αMEM (Thermo Fisher Scientific) supplemented with 10% 
(v/v) FBS (Nichirei), 5 ng/mL FGF2 and 0.5% penicillin and streptomycin (Thermo Fisher Scientific). The 
FOP-iPSCs used in this study (previously described as vFOP4-1 (Matsumoto et al., 2013)) harbor the R206H 
heterozygous mutation in ACVR1, and gene-corrected resFOP-iPSCs were generated by BAC-based 
homologous recombination. These cells fulfilled several criteria for iPSCs including the expression of 
pluripotent markers, teratoma formation, normal karyotype and morphology. Growth and gene expression 
profiles of the resFOP-iPSC clones were indistinguishable from the original FOP-iPSCs (Matsumoto et al., 
2015), however, remarkably distinct responsiveness to Activin-A was observed (Hino et al., 2015). C3H10T1/2 
(murine multipotent mesenchymal cells)-expressing Dox-inducible hINHBA (C3H-DoxOn-hINHBA) was 
maintained in DMEM (Nacalai Tesque) supplemented with 10% FBS and 1 mM Na-pyruvate (Thermo Fisher 
Scientific) and used for an Activin-A-induced HO model transplanted with FOP-iMSCs as previously reported 
(Hino et al., 2015). In the wound healing assay, healthy control iPSC (414C2)-derived iMSCs were used (Okita 
et al., 2011). 
 
Reagents. Activin-A, BMP-4, BMP-7 and TGF-β3 were purchased from R&D Systems. Rapamycin was 
purchased from MedChemexpress. SB-431542 was purchased from Sigma-Aldrich. TAK 165, PD 161570, CP-
724714 and Lapatinib were purchased from Selleck Chemicals. DMH-1 was purchased from Tocris Bioscience. 
AZD0530 was purchased from ANgene. Trastuzumab and Pertuzumab were purchased from BioVision or 
Creative-Biolabs, respectively. Activin-A, BMP-7 and TGF-β3 were dissolved according to the manufacturer’s 
protocols and used at 100 ng/mL (Activin-A and BMP-7) or 10 ng/mL (BMP-4 and TGF-β3) unless otherwise 
noted. 
 
Chemicals Libraries. All chemical libraries were purchased from the suppliers listed. Almost all compounds 
were bioactive and/or annotated. 
Library Name Supplier Number 
Microsource International Drugs MicroSource Discovery Systems 238 Microsource US Drugs 1020 
Enzo FDA 
Enzo Life Sciences 
636 
Enzo ICCB 474 
Enzo kinase inhibitors 76 
LOPAC1280 Sigma-Aldrich 1280 Sigma Pfizer 74 
Myriascreen TimTec 72 
EMD Kinase Inhibitors Merck Millipore 244 
Selleck kinase inhibitors Selleck Chemicals 141 
Tocrs Mini Selected for CiRA Tocris Bioscience 637    
Total  4892 
 
2 
Generation of ATDC5 stably expressing ACVR1. WT- or FOP-ACVR1 was inserted into doxycycline (Dox)-
inducible vector KW111 (Woltjen et al., 2009), which enables us to easily produce stably expressing cell lines 
utilizing the piggyBac (PB) transposon system from the cabbage looper moth Trichoplusia ni (Ding et al., 2005) 
(KW111/WT-ACVR1 or KW111/FOP-ACVR1). KW111/WT-ACVR1 or KW111/FOP-ACVR1 and PBaseII 
plasmid (PB transposase expression vector) (Matsui et al., 2014) were co-transfected into ATDC5 cells by 
FuGeneHD® (Promega) according to the manufacturer’s protocol, and the neomycin-resistant population (500 
µg/mL) was selected. Further selection was performed by selecting a mCherry high positive population (< 5%) 
after six hours of Dox treatment, sorting it with fluorescent-activated cell sorting (FACS) using AriaII (BD) 
according to the manufacturer’s protocol, and designating it as ATDC5/WT-ACVR1 or ATDC5/FOP-ACVR1. 
KW111 included PB, active transposable PB elements; TRE-mCMVP, Tetracycline Response Element and a 
minimal CMV promoter; rtTA, reverse tetracycline-controlled transactivator. PBaseII was an expression 
plasmid vector containing the PB transposase cDNA with optimized codon usage to human under the control 
of the CAG promoter (Matsui et al., 2014). 
 
HTS campaign and follow-up screens. ATDC5/FOP-ACVR1 cells were plated in 96-well white plates 
(2,000 cells/well/40 µL, Corning) in DMEM/F-12 supplemented with 5% (v/v) FBS. Two hours after incubation 
at 37 °C under 5% CO2, 10 µL of test compounds (final 1 µM) was added, and assay plates were incubated at 
37 °C under 5% CO2. After 3 days incubation, Alkaline Phosphatase activity (ALP) or AlamarBlue activity was 
measured using Amplite™ Colorimetric Alkaline Phosphatase Assay Kit (AAT Bioquest) or alamarBlue® Cell 
Viability Reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol, respectively. The 
absorbance at 400 nm (Abs for ALP) or Relative Fluorescent Unit of Ex560/Em590 nm (RFU for AlamarBlue) 
was measured on POWERSCAN4 (DS Pharma Biomedical) or EnVision® Multilabel Reader (PerkinElmer). 
Inhibitory effects of the screened compounds are given as percent inhibition, which was calculated using the 
following equation: (1-([Abs of compound] - [Abs of Min])/([Abs of Max] - [Abs of Min]))× 100, where [Abs 
of Max] and [Abs of Min] are the mean Abs of DMSO control and 1 µM DMH-1, respectively. The Z’ factor, 
which is widely used as a measure of the assay quality of each plate, was calculated using the following 
equation: Z’ factor = 1 - 3 × ([SD of Max] + [SD of Min])/([Abs of Max] - [Abs of Min]) (SI Appendix, Fig. 
S3A). The average Z’ factor in the HTS assay was 0.74, indicating accuracy and reliability of the HTS campaign 
(general criteria of HTS > 0.50) (Zhang et al., 1999). The S/B (signal-to-background) ratio was calculated using 
the following equation: ([Abs of Max]/[Abs of Min]) (SI Appendix, Fig. S3B). The average S/B ratio in the 
HTS assay was 6.9, also indicating accuracy and reliability of the HTS campaign (general criteria of HTS > 
3.0).  
 Using ATDC5/FOP-ACVR1 cells, we performed a first screening (n=2; test compounds = 1 µM, Fig. 
2A and B) against 4,892 small molecule compounds. In the first screening, 160 hit compounds satisfied the 
criteria more than 40% inhibition of ALP activity against DMSO control cells, less than 40% inhibition of 
viability, and margin (Inhibition of ALP activity (%) - Inhibition of viability (%)) more than 20%. A second 
screening was performed against the above 160 compounds (n=2; test compounds = 0.1, 0.3, 1, 3 µM), and 79 
hit compounds satisfied the criteria 40% inhibition of ALP activity against DMSO control cells and margin 
more than 50% at any dose (SI Appendix, Fig. S4 and S5). To explore compounds which have the potential to 
identify new mechanisms or contribute to future drug repositioning, we selected 14 compounds, and detailed 
concentration-dependent assays were performed (Fig. 2E and SI Appendix, Fig. S6). As a result, we identified 
7 compounds which showed stronger IC50 (< 500 nM) and less toxicity (Viability @ 10 µM > 50%) through 
the HTS campaign that focused on the constitutive activity of FOP-ACVR1 (Fig. 2E, red). 
 
2D chondrogenic induction. Chondrogenic induction was performed, and differentiation properties were 
assayed as previously described (Hino et al., 2015; Nasu et al., 2013; Umeda et al., 2012). Briefly, iMSCs (1.5 
× 105) were cultured in fibronectin-coated 24-well plates (BD Biosciences) using the chondrogenic medium 
with 100 ng/mL Activin-A and inhibitors until day 7 unless otherwise noted. Gene-specific siRNAs were 
purchased from Thermo Fisher Scientific (Silencer® Select Pre-designed siRNA). For the transient expression 
of siRNA, Lipofectamine® RNAiMAX Reagent (Thermo Fisher Scientific) was used according to the 
manufacturer's instructions. Knockdown efficiencies (n=1) of MTOR and ERBB2 16 h after transfection in 




Gene ID Sense Antisense 
MTOR s604 GGAGCCUUGUUGAUCCUUAtt UAAGGAUCAACAAGGCUCCat 
ERBB2 s611 GCUCAUCGCUCACAACCAAtt UUGGUUGUGAGCGAUGAGCac 
 
Cardiotoxin-induced HO model in human FOP-ACVR1 conditional transgenic mice. Female hFOP-
ACVR1 conditional transgenic mice (Beard et al., 2006; Hino et al., 2017; Ohnishi et al., 2014; Yamada et al., 
2013) (f5-6 offspring of chimeric mice, age- and body weight-matched between groups) were used between 16 
and 20 weeks of age. Mice were administered 2 mg/mL Dox in their drinking water supplemented with 10 
mg/mL sucrose to induce FOP-ACVR1. Cardiotoxin (9.1 µg/mouse, Latoxan) was injected into the right 
gastrocnemius muscle to initiate skeletal muscle injury and subsequent heterotopic bone formation 
(Chakkalakal et al., 2012). Test compounds (16% DMSO in 0.5 w/v% Methyl Cellulose 400) were 
intraperitoneally administered once a day, five times a week. Mice were analyzed three weeks after injection. 
For X-ray images, mice were anesthetized with isoflurane (5% for induction, 2-3% for maintenance, Abbvie), 
immobilized and X-rayed using µFX-1000 (Fujifilm) or DX-50 (Faxitron Bioptics). µCT images were scanned 
using X-ray CT systems (inspeXio SMX-100CT, Shimadzu) and analyzed with TRI/3D-BON software (Ratoc 
System Engineering) according to the manufacturer's instructions. Four weeks after injection, the injected sites 
were harvested, fixed with 4% paraformaldehyde for 24 h, embedded in paraffin, and sectioned and stained 
with HE, von Kossa, Safranin O and anti-Collagen I antibody as previously described (Hino et al., 2015; Umeda 
et al., 2012). 
 
BMP-7-induced HO model mice. BMP-7 (2 µg/mouse) was injected into the right gastrocnemius muscle of 
C57BL/6NJcl mice (6-8 weeks, male, CLEA Japan), and compounds were administered once a day, five times 
a week (intraperitoneal administration). Mice were analyzed 2 weeks after injection.  
 
Activin-A-induced HO model transplanted with FOP-iMSCs. FOP- (right leg) and resFOP-iMSCs (left leg) 
(4 x 106 cells, respectively) were transplanted into the gastrocnemius muscle of NOD/ShiJic-scid Jcl 
(NOD/SCID) mice (8 weeks, male, CLEA Japan) with C3H-DoxOn-hINHBA (5 x 105 cells), which can 
continuously expose Activin-A to the transplanted iMSCs in vivo (Hino et al., 2015). In the Dox-induced group, 
1 mg/mL Dox (Sigma-Aldrich) was administered via drinking water with 10 mg/mL sucrose (Nacalai Tesque) 
for two weeks after transplantation. Compounds were intraperitoneally administered once a day, five times a 
week. Eight weeks after transplantation, the transplanted cells were harvested, fixed with 4% paraformaldehyde 
for 24 h, embedded in paraffin, and sectioned and stained with HE, von Kossa, Safranin O, human specific anti-
Vimentin antibody and Collagen I antibody as previously described (Hino et al., 2015; Umeda et al., 2012; 
Yamashita et al., 2015). 
 
Histological analysis of growth plates chondrocytes. Knee joints were obtained from BMP-7-injected and 
test compounds-administrated C57BL/6NJcl mice after 2 weeks treatment and fixed, paraffin-embedded, and 
sectioned and stained with Safranin O. The thickness of the proliferative and hypertrophic zones of the growth 
plate were measured using ImageJ software on images obtained using a Keyence microscope (Keyence 
America). The proliferative zone was defined as the region with flat chondrocytes stacked in longitudinal 
columns, and the hypertrophic zone as the region where chondrocytes are enlarged in size and form clusters. 
 
Normal bone µCT. The left legs of mice were obtained from BMP-7-injected and test-compounds 
administrated C57BL/6NJcl mice after 2 weeks treatment. The region of interest (ROI) included the femur-tibia 
(entire femur in addition to the part of tibia above tibia/fibular junction). 
 
Wound healing assay. Healthy control iPSC (414C2)-derived iMSCs (5x104) were cultured in 24-well plates 
using αMEM supplemented with 10% (v/v) FBS, 5 ng/mL FGF2 and 0.5% penicillin and streptomycin at 37 °C 
for 72 h to form a confluent monolayer. Gaps were created by scratching the plates with a sterile pipette tip 
(1000 µL). The cells were then washed with PBS to remove the detached cells and replaced with medium 
containing 1% (v/v) FBS in the presence of DMSO (control) or test compounds (10 nM Rapamycin or 1 µM 
TAK165). The cell culture plates were transferred to a Biostation CT (Nikon Corp., Tokyo, Japan) programmed 
to take photographs at t = 0 h and t = 24 h. The migrated area was determined by subtracting the wound area at 
4 
time point t = 24 h from t = 0 h, and relative cell migration was expressed as the ratio of the absolute cell 
migrations between the experimental and control groups by using CL-Quant software (Nikon Corp.).  
 
Quantitative PCR analysis. Total RNA was purified with RNeasy Kit (Qiagen) and treated with DNase-one 
Kit (Qiagen) to remove genomic DNA. Total RNA (0.3 µg) was reverse transcribed for single-stranded cDNA 
using random primers and Superscript III reverse transcriptase (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Quantitative PCR was performed with Thunderbird SYBR qPCR Mix (TOYOBO) 
and analyzed with the StepOne real-time PCR system (Applied Biosystems). All data (relative expression) were 
corrected by β-actin. 
 
Primers for RT-qPCR. 
Gene Forward Reverse 
ACTB CACCATTGGCAATGAGCGGTTC AGGTCTTTGCGGATGTCCACGT 
MTOR GACGAGAGATCATCCGCCAG ACAAGGGACCGCACCATAAG 
ERBB2 GCTCCTCCTCGCCCTCTT TGAGTTCCAGGTTTCCCTGC 
 
Microarray experiments. 2D chondrogenic induction was performed in FOP-iMSCs stimulated with or 
without 100 ng/mL Activin-A, TAK 165, CP-724714 and Lapatinib. Seven days after incubation, mRNA was 
extracted. RNA was reverse transcribed, biotin-labeled and hybridized to GeneChip Human Gene 1.0 ST 
Expression Array, which was subsequently washed and scanned according to the manufacturer’s instructions 
(Affymetrix). Raw CEL files were imported into GeneSpring GX 12.6.1 software (Agilent Technologies), and 
expression values were calculated with the RMA16 algorithm. Pathway analysis was performed by Ingenuity 
pathway analysis (Qiagen).  
 
Western blotting. SDS-PAGE and blotting with whole-cell lysates were performed by standard procedures. 
Protein bands were detected with ECL Prime Western Blotting Detection Reagent (GE Healthcare) and 
visualized using BIO-RAD Molecular Imager® Chemi-DocTM XRS+ with Image LabTM software (Bio-Rad). 
All data (relative intensity) were corrected by β-actin. 
 
Antibodies for western blotting and immunostaining. 
 Name Company Cat. No Concentration 
1st antibody 
Human Activin RIA/ALK-2 Antibody R&D Systems) AF637 1:100 
Phospho-S6 Ribosomal Protein (Ser235/236) 
Antibody 
Cell Signaling 
Technology #2211 1:1000 
Monoclonal Anti-b-Actin-Peroxidase clone AC-15 SIGMA-ALDRICH A3854 1:200000 
Anti-human Vimentin antibody Abcam ab16700 1:40 





Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technology #7074 1:10000 
Goat anti-Rabbit IgG (H+L) Secondary Antibody,  
Alexa Fluor® 488 conjugate Invitrogen A-11008 1:100 
Goat anti-Rabbit IgG (H+L) Secondary Antibody,  
Alexa Fluor® 555 conjugate Invitrogen A-21428 1:500 
 
GAG value. The GAG content was quantified in pellets with the Blyscan Glycosaminoglycan Assay Kit 
(Biocolor). The DNA content was quantified using PicoGreen dsDNA Quantitation Kit (Thermo Fisher 
Scientific). 
 
Immunohistochemistry. Paraffin-embedded sections were deparaffinized. For human specific anti-Vimentin 
antibody, antigen retrieval was performed by autoclave (105 °C, 10 min). Samples were blocked with Blocking 
One (Nacalai Tesque) for 60 min and then incubated with human specific anti-Vimentin antibody (Abcam) or 
5 
anti-Collagen I antibody (Novus Biologicals) diluted in Can Get Signal® immunostain solution B (TOYOBO) 
for 16-18 h at 4 °C. Next, samples were washed several times in 0.2% tween20 (Sigma-Aldrich) in PBS and 
incubated with Goat anti-Rabbit IgG (H+L) secondary antibody, Alexa Fluor® 488 or 555 conjugate (Thermo 
Fisher Scientific) diluted in Can Get Signal® immunostain solution B for one hour at room temperature. DAPI 
(10 µg/mL) was used to counterstain nuclei. Samples were observed by BZ-9000E (KEYENCE). 
 
Statistics. The statistical significance of all experiments was calculated by Prism 6 (GraphPad Software). P 
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Figure S1. Expression of ACVR1 and mCherry in ATDC5/WT-ACVR1 or 
ATDC5/FOP-ACVR1. Related to Figure 1. 24 h after Dox treatment (0-2 µg/mL), 
cells were fixed and stained. Panels of DOX 0 and 0.002 µg/mL condition are 
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Figure S2. Dose-dependent assay results of 79 hit compounds. Related to Figure
2. ALP assay and AlamarBlue assay were performed using the same protocol as 
the HTS. Results are the mean of biological duplicate. 0.1, 0.3, 1, 3 µM of test 
compounds were assessed. Listed compounds showed more than 40% inhibition 
of ALP activity against DMSO control cells and margin more than 50% (inhibition 
















Figure S3. AZD0530 and TAK 165 suppressed BMP-7-induced HO. Related to 
Figure 5. BMP-7 was injected into the right gastrocnemius muscle of male 
C57BL/6 mice (6-8 weeks), who were administered drugs once daily 5 times a 
week intraperitoneally for 2 weeks thereafter. (A) X-rays (upper panels) and 
µCT (lower panels) observations. (B) Average heterotopic bone volume. (C) 
The number of mice harboring HO (> 20 mm3 bone volume). (D) Body weight 
change of BMP-7-injected male C57BL/6 mice. Scale bars, 10 mm (A). Results 
are the mean ± standard error (SE). N = 5. *,  P < 0.05; **, P < 0.01 by 
Dunnett’s multiple comparisons t-test compared to the vehicle treatment group 
(B). No significant differences between the AZD- or TAK- administered group 
compared to the vehicle group in two-way repeated measures ANOVA followed 
by Dunnett's multiple comparisons t-test (D).

































Figure S4. Tests of side effects of direct and indirect mTOR inhibitors. Related 
to Figure 5 and 6. (A-E) BMP-7 was injected into the right gastrocnemius 
muscle of male C57BL/6 mice (6-8 weeks), who were administered 5 mg/kg of 
compounds once daily 5 times a week intraperitoneally for 2 weeks thereafter. 
(A-C) Histological analysis of growth plate chondrocytes. Representative 
histological sections of the growth plate of tibiae from compounds-administered 
mice (A). Quantification of the thickness of the proliferative (B) and hypertrophic 
(C) zones is shown. Vertical lines indicate proliferative (black) and hypertrophic 
(white) zones. (C and D) Normal bone µCT of the femur-tibia of left legs from
compounds-administered mice (F and G) Wound healing assay using iMSCs 
from healthy donor-derived iPSCs (414C2). iMSCs migrated to cover the 
scratched cell-free area. (E) Representative pictures and (F) relative migration 
values of iMSCs cultured in the medium with DMSO or test compounds (10 nM
rapamycin or 1 µM TAK165). Scale bars, 0.5 mm (A and F). Results are the 
mean ± standard error (SE), n = 5 (Vehicle and TAK 165) or n = 4 (rapamycin) 
(A-E), or biological triplicate in 3 independent experiments (F and G). n.s., no 
significant difference by Dunnett’s multiple comparisons t-test compared to the 
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Figure S5. Analysis of the mechanism of TAK 165 action. Related to Figure 7.
(A and B) ERBB2 inhibition did not suppress the chondrogenic induction of 
FOP-iMSCs. (A) Lapatinib (selective EGFR/ERBB2 inhibitor) and CP-724714 
(selective ERBB2 inhibitor) or (B) 1 µg/mL Trastuzumab and 1 µg/mL 
Pertizumab (neutralizing antibodies against ERBB2 ) did not suppress the 
chondrogenesis of FOP-iMSCs. FOP-iMSCs were harvested 7 days after 
chondrogenic induction, which was performed with or without Activin-A, ERBB2 
inhibitors or antibodies. TAK, 1 µM TAK 165; Rapa, 20 nM rapamycin. (C) TAK 
165 suppressed the chondrogenesis of FOP-iMSCs stimulated with TGF-β3. 
(D) TAK 165 suppressed the chondrogenesis of resFOP-iMSCs stimulated with 
Activin-A. resFOP- or FOP-iMSCs were harvested 7 days after chondrogenic 
induction, which was performed with or without Activin-A or TGF-β3. Results 
are the mean ± standard error (SE) of biological triplicate using FOP-iPSCs 
(vFOP4-1) or its isogenic control iPSCs (resFOP-iPSCs). n.s., no significant 
difference; *, P < 0.05; ***, P < 0.001 by Dunnett’s multiple comparisons t-test 
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Figure S6. Distinct effects of AZD0530, PD 161570 and TAK 165 on mTOR 
signaling in chondrogenesis of FOP-iMSCs. Related to Figure 7. After 2 h (A), 
24 h (B) or 7 days (C) of chondrogenic induction of FOP-iMSCs with Activin-A 
and test compounds, the cells were harvested, and p-S6 was assessed by 
western blotting. 10 nM rapamycin (Rapa) or 1 µM TAK 165 (TAK), AZD0530 
(AZD) and PD 161570 (PD) were applied in the experiments. Results are the 
mean ± standard error (SE) of biological triplicate in 3 independent experiments 
using FOP-iPSCs (vFOP4-1). n.s., no significant difference; **, P < 0.01; ***, P < 
0.001 by Dunnett’s multiple comparisons t-test compared to the DMSO 





















































Figure S7. Pathway analysis of TAK 165 and other ERBB2 inhibitors in Activin-
A-induced chondrogenesis of FOP-iMSCs. Related to Figure 7. Chondrogenic 
induction was performed in FOP-iMSCs with or without 100 ng/mL Activin-A, 
100 nM TAK 165, 100 nM Lapatinib (selective EGFR/ERBB2 inhibitor) and 100 
nM CP-724714 (selective ERBB2 inhibitor). After 7 days, cells were harvested, 
and microarray analysis was performed. (A) Experimental group and 
stimulation. (B and C) Differentially expressed genes (1.5 fold change) against 
the TAK 165-treated group were analyzed by Ingenuity Pathway Analysis. (B) 
Canonical Pathways significantly involved in all three groups. –log (p-value) > 
1.3 (p = 0.05) was considered significant. (C) Expression ratio to the TAK 165-
treated group of differentially expressed genes in “Role of Osteoblasts, 
Osteoclasts and Chondrocytes in Rheumatoid Arthritis” are shown.  N = 1. 
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Symbol Entrez Gene Name (-) Lapatinib CP-724714
MMP1 matrix metallopeptidase 1 3.6 3.0 11.5
MMP13 matrix metallopeptidase 13 5.6 6.9 5.4
ITGA3 integrin subunit alpha 3 2.1 2.5 3.9
ITGB3 integrin subunit beta 3 2.8 3.6 3.3
FOS Fos proto-oncogene, AP-1 transcription factor subunit 2.2 2.4 3.2
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif 5 0.5 2.1 3.1
BMP4 bone morphogenetic protein 4 0.5 0.4 5.2
DKK1 dickkopf WNT signaling pathway inhibitor 1 0.5 2.1 0.2
FRZB frizzled-related protein 2.7 3.0 3.6
FZD3 frizzled class receptor 3 0.5 0.4 0.3
PIK3R3 phosphoinositide-3-kinase regulatory subunit 3 2.0 2.1 0.4
SPP1 secreted phosphoprotein 1 2.9 3.7 4.4
TNFRSF11B TNF receptor superfamily member 11b 0.5 0.5 3.4
WIF1 WNT inhibitory factor 1 0.2 0.1 0.1
WNT16 Wnt family member 16 2.3 0.5 3.0
C
